MERCK KGAA'S L-BLP25 TRIAL DID NOT MEET PRIMARY ENDPOINT (ENG)

     (The following press release from Merck KGaA was received by e-mail. It 
was not confirmed by the sender.) 
News Release 
Your Contact
Phyllis Carter
+49 6151 72-7144 
Merck: Detailed Results of Phase III Trial of L-BLP25 in Patients With
Non-Small Cell Lung Cancer (START) to be Presented at ASCO 
• Confirmed: Primary endpoint of significantly improving overall survival
not
 met
• Predefined subgroup of patients receiving initial concurrent
 chemoradiotherapy: median overall survival of 30.8 months observed in
 patients treated with L-BLP25 compared to 20.6 months in patients
receiving
 placebo (HR 0.78, p=0.016) in post hoc analysis
• Detailed results to be presented on Tuesday, June 4 
Darmstadt, May 16, 2013 – Merck announced today detailed results from the
randomized Phase III START* trial of its investigational MUC1
antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as
Stimuvax) in patients with unresectable, locally advanced Stage III
non-small cell lung cancer (NSCLC). These results will be presented at the
American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in
Chicago. The primary endpoint of improving overall survival (OS) was not
met. In a predefined subgroup of patients receiving initial concurrent
chemoradiotherapy (CRT), a combination of chemotherapy and radiotherapy
given at the same time, a median overall survival of 30.8 months versus
20.6 months was observed based on a post hoc analysis in patients treated
with L-BLP25 versus placebo respectively (HR 0.78, 95% CI 0.64–0.95,
p=0.016, n=806). The results of the START trial will be presented during
the Oral Abstract Session “Lung Cancer – Non-Small Cell Local-Regional /
Small Cell / Other Thoracic Cancers” from 09.45 am to 12.45 pm on Tuesday,
June 4. 
The complete news release can be downloaded at the following link:
http://news.merck.de/N/0/D589CE5EF4A133A7C1257B6C0046F5EA/$File/Start_Asco_engli
sch.pdf 
News releases from Merck KGaA, Darmstadt, Germany, are available at this
address:
www.merckgroup.com/media or for residents in the USA and Canada at
www.emdgroup.com/media 
In case you are a resident of the USA or Canada please go to
http://www.emdgroup.com/subscribe to register again for your online
subscription of this service as our newly introduced geo-targeting requires
new links in the email. 
You may change your subscription at any time by following either one of the
following links:
www.merckgroup.com/subscribe or www.emdgroup.com/subscribe
And please feel free to unsubscribe this service with either
www.merckgroup.com/subscribe or www.emdgroup.com/unsubscribe
Thank you very much! 
Merck KGaA ,Darmstadt, Germany
External Communications
E-mail: Media.Relations@merck.de
Hotline: +49 (0) 6151/72-5000 
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient,
you must not copy this message or attachment or disclose the contents to
any other person. If you have received this transmission in error, please
notify the sender immediately and delete the message and any attachment
from your system. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not accept liability for any omissions or errors in this
message which may arise as a result of E-Mail-transmission or for damages
resulting from any unauthorized changes of the content of this message and
any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not guarantee that this message is free of viruses and does
not accept liability for any damages caused by any virus transmitted
therewith. 
Click http://disclaimer.merck.de to access the German, French, Spanish and
Portuguese versions of this disclaimer.